BN Business News
Add your company to Business Communicator →

Business · 12/04/2016

EMD Serono Withdraws FDA Approval for LUVERIS

EMD Serono has voluntarily withdrawn its new drug application for LUVERIS, a treatment for growth hormone deficiency, from the FDA, waiving its right to a hearing.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights